These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 29374168

  • 1. Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer.
    Li H, Liu L, Chang H, Zou Z, Xing D.
    Cell Death Dis; 2018 Jan 26; 9(2):137. PubMed ID: 29374168
    [Abstract] [Full Text] [Related]

  • 2. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
    Pétigny-Lechartier C, Duboc C, Jebahi A, Louis MH, Abeilard E, Denoyelle C, Gauduchon P, Poulain L, Villedieu M.
    Mol Cancer Ther; 2017 Jan 26; 16(1):102-115. PubMed ID: 27980105
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein.
    Preuss E, Hugle M, Reimann R, Schlecht M, Fulda S.
    J Biol Chem; 2013 Dec 06; 288(49):35287-96. PubMed ID: 24133218
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
    Goodwin CM, Rossanese OW, Olejniczak ET, Fesik SW.
    Cell Death Differ; 2015 Dec 06; 22(12):2098-106. PubMed ID: 26045046
    [Abstract] [Full Text] [Related]

  • 11. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
    Chen S, Dai Y, Pei XY, Myers J, Wang L, Kramer LB, Garnett M, Schwartz DM, Su F, Simmons GL, Richey JD, Larsen DG, Dent P, Orlowski RZ, Grant S.
    Cancer Res; 2012 Aug 15; 72(16):4225-37. PubMed ID: 22693249
    [Abstract] [Full Text] [Related]

  • 12. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S, Ricciardi MR, Allegretti M, Mirabilii S, Licchetta R, Bergamo P, Rinaldo C, Zeuner A, Foà R, Milella M, McCubrey JA, Martelli AM, Tafuri A.
    Oncotarget; 2015 Oct 13; 6(31):32089-103. PubMed ID: 26392332
    [Abstract] [Full Text] [Related]

  • 13. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
    Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, Boisvert JL, Milano RJ, Roper J, Kodack DP, Jain RK, Corcoran RB, Rivera MN, Ramaswamy S, Hung KE, Benes CH, Engelman JA.
    Cancer Discov; 2014 Jan 13; 4(1):42-52. PubMed ID: 24163374
    [Abstract] [Full Text] [Related]

  • 14. Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263.
    Shao H, Jing K, Mahmoud E, Huang H, Fang X, Yu C.
    Mol Cancer Ther; 2013 Dec 13; 12(12):2640-50. PubMed ID: 24126433
    [Abstract] [Full Text] [Related]

  • 15. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.
    Lee JS, Tang SS, Ortiz V, Vo TT, Fruman DA.
    Oncotarget; 2015 Nov 03; 6(34):35202-17. PubMed ID: 26460954
    [Abstract] [Full Text] [Related]

  • 16. Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.
    Zhang L, Wang H, Li W, Zhong J, Yu R, Huang X, Wang H, Tan Z, Wang J, Zhang Y.
    Oncotarget; 2017 Jan 10; 8(2):3289-3303. PubMed ID: 27924057
    [Abstract] [Full Text] [Related]

  • 17. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
    Cai J, Xia J, Zou J, Wang Q, Ma Q, Sun R, Liao H, Xu L, Wang D, Guo X.
    FEBS Open Bio; 2020 Apr 10; 10(4):535-545. PubMed ID: 32027103
    [Abstract] [Full Text] [Related]

  • 18. Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells.
    Pandey MK, Gowda K, Doi K, Sharma AK, Wang HG, Amin S.
    PLoS One; 2013 Apr 10; 8(11):e78570. PubMed ID: 24223823
    [Abstract] [Full Text] [Related]

  • 19. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
    Torki S, Soltani A, Shirzad H, Esmaeil N, Ghatrehsamani M.
    Biomed Pharmacother; 2017 Aug 10; 92():39-45. PubMed ID: 28528184
    [Abstract] [Full Text] [Related]

  • 20. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K, Redalen KR, Sønstevold L, Bjørnetrø T, Sølvernes J, Ree AH.
    BMC Cancer; 2016 Jul 26; 16():531. PubMed ID: 27461218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.